Avacta Group PLC Manchester ShareSoc Growth Company Seminar
04 July 2017 - 4:00PM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
04 July 2017
4 July 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at Manchester ShareSoc Growth Company
Seminar
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, is pleased to announce that
its Chief Executive, Alastair Smith, will be presenting at the
ShareSoc Growth Company Seminar on Tuesday 11(th) July at the
Double Tree by Hilton Manchester Piccadilly Hotel, 1 Piccadilly
Place, 1 Auburn Street, Manchester M1 3DG.
The evening event, which begins with registration at 17:30,
provides an opportunity for investors to hear about the Company's
Affimer(R) technology, its development plans and to discuss these
with Alastair.
ENDS
NOTES
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207 220
Geoff Nash / Giles Rolls 0500
- Nominated Adviser www.finncap.com
Tim Redfern / Alice Lane
- Corporate Broking
Tel: +44 (0) 203 705
WG Partners 9318
Nigel Birks / Nigel Barnes Tel: +44 (0) 203 705
David Wilson / Claes Spang 9217
www.wgpartners.co.uk
Zyme Communications (Trade Tel: +44 (0)7787 502
and Regional Media) 947
Katie Odgaard katie.odgaard@zymecommunications.com
FTI Consulting (Financial Tel: +44 (0) 203 727
Media and IR) 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Affimer technology has been designed to address many of the
negative performance issues of antibodies, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUGUUAMUPMGUW
(END) Dow Jones Newswires
July 04, 2017 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024